Does the risk of cardiovascular complications decrease in psoriatic patients receiving systemic therapy?;Verbesserung des Risikos vaskulärer Komplikationen bei Patienten mit Psoriasis vulgaris unter Systemtherapie?

Hautarzt

Volumn 64, Issue 1, 2013, Pages 63-64

  Glaser R ^a   Gerdes, S ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; PSORIASIS; RISK ASSESSMENT; SYSTEMIC THERAPY;

EID: 84872914321     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-012-2522-9     Document Type: Article

References (6)

1. Gerdes S, Mrowietz U (2012) Komorbiditäten und Psoriasis. Hautarzt 63:202-213
2. Wu JJ, Poon K-YT, Channual JC et al (2012) Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol (online first 20 Aug 2012)
3. Prodanowich S, Fangchao M, Taylor JR et al (2004) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262-267
4. Lan CC, Ko YC, Yu HS et al (2012) Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol 92:349-352
5. Abuabara K, Lee H, Bimball AB (2011). The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 165:1066-1073
6. Boehncke S, Fichtlscherer S, Salgo R et al (2011) Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303:381-388